QuidelOrtho Corporation enters the post-earnings stretch with a painful earnings miss confirmed, an analyst slashing its price target in half, and short sellers showing no sign of relenting.
The stock closed at $11.66 on May 5, down 6% on the day and off 32% over the past month. Q1 revenue came in at $619.8 million — well below the prior year's $692.8 million — as a 30% softer respiratory season hit the top line hard. Net loss widened to $91.8 million from $12.7 million a year earlier. Those numbers drove the day's selloff and set up the rest of this note.
The most immediate Street reaction came from Citigroup. Patrick Donnelly slashed his price target from $30 to $13 on May 6 — a 57% cut — while staying at Neutral. The move is striking: just three months ago, in February, Donnelly had raised his target to $30. That reversal captures how quickly the investment case has deteriorated. UBS had already moved similarly in April, trimming its own target from $30 to $17 while holding Neutral. JPMorgan carries an Underweight with a $22 target set last November — currently the most optimistic on the board. With the consensus mean price target now at $23.60 and the stock trading at $11.66, targets are running at double the current price. That gap reflects analysts anchored to recovery assumptions that the Q1 print has put in serious doubt. The analyst community has been persistently neutral-to-bearish: every firm tracked here is either Hold-equivalent or Underweight. There are no upgrades in the recent data.
Short sellers remain firmly positioned, and the earnings miss reinforces why. Short interest is running at 18.7% of the free float — up from roughly 16.2% in late March, a two-month build of around 2.5 percentage points. A notable drop occurred around April 9-10, when SI fell from near 19.8% to 15.9% as some shorts covered. That proved temporary. Positioning rebuilt through April and now sits back near the prior peak. Borrow is cheap — cost to borrow recently fell to 0.48%, down 21% on the week and off 15% over the past month — which means new short supply is plentiful and there is no technical squeeze pressure in the lending market. Availability is ample. The ORTEX short score of 62.9 has been drifting higher over the past two weeks, consistent with steady pressure rather than any rapid escalation. Days to cover from the most recent FINRA settlement stands at 6.4 days — elevated, but not extreme.
Options positioning has also turned defensive since April. The put/call ratio was running near 0.59 as recently as late March. It has more than doubled to 1.41, sitting about one standard deviation above its 20-day mean of 1.02. While this is not at the 52-week extreme of 2.60, the direction of travel is clearly towards more hedging. Demand for downside protection picked up sharply in the final week of April and has held there through the earnings print.
The earnings call narrative adds crucial texture to the numbers. CEO Brian Blaser attributed the Q1 shortfall to three distinct pressures: a milder respiratory season (ILI visits down ~30% year-on-year, an industry-wide dynamic), macroeconomic caution from Chinese distributors ahead of national IVD pricing guidelines, and order delays from Middle East disruption. The China headwind is the one to watch — final pricing guidelines have not been issued, and management acknowledged the revenue impact estimate could change. The acquisition of LEX Diagnostics in April, adding a molecular platform at point-of-care, represents the strategic pivot to future growth, but management guided for instrument placements this quarter with revenue beginning in early 2027. That timeline keeps any upside firmly in the future.
Institutional holders offer an interesting backdrop. Invesco filed a Schedule 13G/A on May 6, the same day as Citigroup's cut — its Q1 13F already showed it added 574,000 shares. American Century added 603,000 shares through April 30. FMR added 924,000 shares through February. On balance, some active managers have been buying the dip even as sell-side targets collapsed. That creates the core tension heading into Q2: fundamental deterioration versus a valuation that, at a P/B of 0.40 and an EV/EBITDA of 5.3x, already reflects a deeply distressed business.
The next scheduled print is June 16. Between now and then, the market's attention turns to whether China's IVD pricing guidelines are finalised — and what the actual implementation timeline looks like.
See the live data behind this article on ORTEX.
Open QDEL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
